Results 251 to 260 of about 465,548 (350)

Philadelphia chromosome‐positive acute lymphoblastic leukaemia in children and adolescents: A changing treatment landscape and a methodological challenge

British Journal of Haematology, EarlyView.
Adriana Balduzzi, Maria Grazia Valsecchi, Thai Hoa Tran, Jan Zuna, Veronica Leoni, Gunnar Cario, Grazia Fazio, Virginie Gandemer, Sarah K. Tasian, Inge M. van der Sluis, Nicolò Peccatori, Rosanna Parasole, Stefania Monterisi, Mignon L. Loh, Meenakshi Devidas, Stephen P. Hunger, John A. Kairalla, Paola De Lorenzo, Lewis B. Silverman, Andrea Biondi   +19 more
wiley   +1 more source

Precision Oncology for Pediatric Solid Tumors Using In‐Hospital Pediatric/AYA Malignancy‐Specific Panel Sequencing

Cancer Science, EarlyView.
Our findings indicate that a pediatric/AYA‐specific targeted panel deployed in a hospital can deliver rapid, clinically actionable molecular insights with high diagnostic and prognostic yield. This complements larger sequencing platforms by offering speed, focused content, and easier interpretation.
Masato Kojima, Sho Kurihara, Isamu Saeki, Ryo Touge, Keigo Nakashima, Shuhei Karakawa, Fumiyuki Yamasaki, Satoshi Okada, Eiso Hiyama   +8 more
wiley   +1 more source

Peripheral Blood CD4/CD8 Ratio Predicts Out-of-Specification Products in Lisocabtagene Maraleucel Manufacturing. [PDF]

Cancer Rep (Hoboken)
Hirano T, Tatetsu H, Ueno S, Shichijo T, Nakamura T, Yamada A, Uchiba M, Kato K, Nosaka K, Matsuoka M, Yasunaga JI.   +10 more
europepmc   +1 more source

Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study [PDF]

, 2018
et al,, Gambacorti-Passerini, Carlo, Van Tine, Brian A   +2 more
core   +1 more source

T‐cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia

British Journal of Haematology, EarlyView.
Maria L. Andersson, Olina Lind, Kia Heimersson, Anna Berglöf, Teresa del Peso Santos, Lucía Peña‐Pérez, Qing Wang, Tom A. Mulder, Rula Zain, Robert Månsson, Richard Rosenquist, C. I. Edvard Smith, Anders Österborg, Marzia Palma   +13 more
wiley   +1 more source

Expression of the CXCR4 S338X Variant Improves Anti‐Leukemia Efficacy of Anti‐CD19 CAR‐T Cells

Cancer Science, EarlyView.
Under normal conditions, CXCL12 stimulation induces CXCR4 degradation. In contrast, CAR19‐T cells expressing the CXCR4 S338X variant maintain receptor stability and sustain ERK and AKT signaling, which supports T‐cell effector function, migration, and survival. Therefore, the enhanced anti‐leukemic activity is conferred by CXCR4 S338X expression in CAR‐
Yushu Mao, Xiaodan Wang, Chun‐Hui Jin, Zhifeng Wei, Qinghao Ding, Ke‐Ke Zhang, Bo‐Wen Dong, Kai‐Wen Zheng, Yufei Hou, Tao Zhang, Wen‐Jie Zhao, Zheng Hu, Yong‐Guang Yang   +12 more
wiley   +1 more source

Comparison of Diagnostic Utilities in a Canine Retrobulbar Large B-Cell Lymphoma With Multifocal Involvement. [PDF]

Vet Med Sci
Jung R, Bae H, Cho KW, Jung DI, Yu D.
europepmc   +1 more source

Cancer‐Specific Antihuman Podoplanin Antibody chLpMab‐2f Exerts Antitumor Effects Against Pleural Mesothelioma

Cancer Science, EarlyView.
Cancer‐specific antihuman podoplanin antibody chLpMab‐2f exerted antibody‐dependent cellular cytotoxicity and complement‐dependent cytotoxicity against pleural mesothelioma (PM) cell lines. Additionally, chLpMab‐2f inhibited tumor progression in mice with subcutaneously and intrathoracically transplanted human PM cells.
Aito Yoshida, Shinji Abe, Toshihiro Izumi, Satoshi Itakura, Keichiro Yamada, Takuya Wada, Takaaki Yamamoto, Chiemi Sato, Atsushi Mitsuhashi, Hirokazu Ogino, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Mika K. Kaneko, Yukinari Kato, Yasuhiko Nishioka   +15 more
wiley   +1 more source

Efficacy of PR2-based immunotherapy in the treatment of diffuse large B-cell lymphoma-associated neurolymphomatosis: A report on two cases. [PDF]

Ann Hematol
Wang X, Zhang Q, Zhou H, Li W, Liu H, Hou X, Zu J, Sang W.   +7 more
europepmc   +1 more source